QIAGEN Companion Diagnostic Wins FDA Approval for use With IRESSA

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. CRWD
2. AAPL
3. PLTR
4. LITE
5. REGN
6. MRVL
7. ABBV
8. CHKP
9. MAR
10. CL

Go back to QIAGEN Companion Diagnostic Wins FDA Approval for use With IRESSA

Piper Jaffray Maintains a Neutral Rating on Qiagen (QGEN) Following Expanded Channel Checks

July 14, 2015 8:02 AM EDT

Piper Jaffray maintains a Neutral rating and $24.00 price target on Qiagen NV (NASDAQ: QGEN) following expanded channel checks. Analyst William Quirk says that the latest checks did not uncover additional transitions from Qiagen to alternative HPV platforms, and views this as a sighn that shares are stabilizing.

Quirk commented,... More

Qiagen (QGEN) Announces Receipt of FDA PMA for Therascreen EGFR Test for Use with IRESSA in NSCLC

July 13, 2015 3:47 PM EDT

Qiagen (NASDAQ: QGEN) received U.S. marketing (PMA) approval of its therascreen EGFR RGQ PCR Kit (therascreen EGFR test) as a companion diagnostic to guide the use of AstraZeneca' (NYSE: AZN) IRESSA (gefitinib) in the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). QIAGEN's therascreen EGFR test was approved by the Food and Drug Administration to enable doctors to identify NSCLC patients who have tumors that are positive for epidermal growth factor receptor (EGFR) mutations and therefore are eligible for treatment with... More